Key Takeaways Novo Nordisk shares gained Monday as the company said it would present new data on the ability of semaglutide, ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk (NYSE: NVO), the Danish company best known as the maker of weight loss drug Wegovy, expanded a little on the ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed ...

Danish company Novo Nordisk's membership in a UK pharmaceutical industry body has been restored after a two-year suspension ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

Novo Nordisk has been accepted back into the fold. Two years after suspending Novo, the Association of the British ...

Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...